WallStreetZenWallStreetZen

NASDAQ: NTRA
Natera Inc Stock

$107.20-0.79 (-0.73%)
Updated Jun 20, 2024
NTRA Price
$107.20
Fair Value Price
N/A
Market Cap
$13.16B
52 Week Low
$36.90
52 Week High
$117.23
P/E
-34.36x
P/B
16.58x
P/S
9.14x
PEG
N/A
Dividend Yield
N/A
Revenue
$1.21B
Earnings
-$365.46M
Gross Margin
50.3%
Operating Margin
-29.14%
Profit Margin
-30.2%
Debt to Equity
0.85
Operating Cash Flow
-$139M
Beta
1.38
Next Earnings
Aug 1, 2024
Ex-Dividend
N/A
Next Dividend
N/A

NTRA Overview

Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. It offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother, as well as twin pregnancies for zygosity; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases; and Spectrum to identify chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle. The company also provides Anora miscarriage test products to analyze fetal chromosomes to understand the cause of miscarriage; and non-invasive paternity testing products to determine paternity by gestation using a blood draw from the pregnant mother and alleged father. In addition, it offers Constellation, a cloud-based software product that enables laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics in order to validate and launch tests; Signatera, a circulating tumor DNA technology that screen for a generic set of mutations independent of an individual's tumor; and Prospera used to assess organ transplant rejection. The company offers products through its direct sales force, as well as through a network of approximately 100 laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was formerly known as Gene Security Network, Inc. and changed its name to Natera, Inc. in 2012. Natera, Inc. was founded in 2003 and is based in Austin, Texas.

Zen Score

Industry Average (26)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how NTRA scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

NTRA is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
NTRA is poor value based on its book value relative to its share price (16.58x), compared to the US Diagnostics & Research industry average (4.19x)
P/B vs Industry Valuation
NTRA is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more NTRA due diligence checks available for Premium users.

Be the first to know about important NTRA news, forecast changes, insider trades & much more!

NTRA News

Valuation

NTRA price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-34.36x
Industry
37.94x
Market
30.97x

NTRA price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
16.58x
Industry
4.19x
NTRA is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation

NTRA's financial health

Profit margin

Revenue
$367.7M
Net Income
-$67.6M
Profit Margin
-18.4%
NTRA's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
NTRA's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$1.5B
Liabilities
$674.1M
Debt to equity
0.85
NTRA's short-term assets ($1.26B) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
NTRA's short-term assets ($1.26B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
NTRA's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
NTRA's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
$27.0M
Investing
$138.3M
Financing
$6.5M
NTRA's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

NTRA vs Diagnostic & Research Stocks

TickerMarket Cap1d %P/EP/B
NTRA$13.16B-0.73%-34.36x16.58x
RVTY$13.26B+0.20%88.11x1.69x
MEDP$12.41B-0.59%39.39x18.48x
DGX$15.35B+0.66%18.35x2.39x
CRL$10.80B-0.08%24.52x2.97x

Natera Stock FAQ

What is Natera's quote symbol?

(NASDAQ: NTRA) Natera trades on the NASDAQ under the ticker symbol NTRA. Natera stock quotes can also be displayed as NASDAQ: NTRA.

If you're new to stock investing, here's how to buy Natera stock.

What is the 52 week high and low for Natera (NASDAQ: NTRA)?

(NASDAQ: NTRA) Natera's 52-week high was $117.23, and its 52-week low was $36.90. It is currently -8.56% from its 52-week high and 190.51% from its 52-week low.

How much is Natera stock worth today?

(NASDAQ: NTRA) Natera currently has 122,802,694 outstanding shares. With Natera stock trading at $107.20 per share, the total value of Natera stock (market capitalization) is $13.16B.

Natera stock was originally listed at a price of $22.74 in Jul 2, 2015. If you had invested in Natera stock at $22.74, your return over the last 8 years would have been 371.42%, for an annualized return of 21.39% (not including any dividends or dividend reinvestments).

How much is Natera's stock price per share?

(NASDAQ: NTRA) Natera stock price per share is $107.20 today (as of Jun 20, 2024).

What is Natera's Market Cap?

(NASDAQ: NTRA) Natera's market cap is $13.16B, as of Jun 21, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Natera's market cap is calculated by multiplying NTRA's current stock price of $107.20 by NTRA's total outstanding shares of 122,802,694.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.